研報掘金丨長江證券:維持愛美客“買入”評級,溶液和凝膠產品保持穩定增長
長江證券研報指出,愛美客(300896.SZ)24年實現歸母淨利潤19.58億元,同比增長5.33%。擬向全體股東每10股派發現金紅利38元(含稅)。2024年全年來看,溶液和凝膠產品保持穩定增長,華北和華南區域表現較好。展望在研產品,公司用於糾正頦部後縮的醫用含聚乙烯醇凝膠微球的交聯透明質酸鈉凝膠已經獲得Ⅲ類醫療器械註冊證;而米諾地爾搽劑、利多卡因丁卡因乳膏、注射用A型肉毒毒素等三個產品的上市許可申請獲得受理,進入審評階段;重組透明質酸酶、司美格魯肽注射液、去氧膽酸注射液獲得國家藥品監督管理局臨牀試驗批件。整體而言,短、中、長期產品儲備較爲豐富。同時,近期公司擬收購韓國REGEN公司控股權,有望進一步豐富再生材料產品線,開拓全球化的市場空間。維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.